Global Pertussis Market Outlook: Trends, Vaccines, and Growth Opportunities to 2034

Pertussis Market Overview: Trends, Treatments, and Opportunities

The Pertussis Market is poised for steady growth, fueled by increasing awareness of whooping cough and the ongoing development of more effective interventions. Leading Pertussis Companies such as Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, and BioNet are driving innovation and shaping the competitive landscape. With a strong focus on vaccine development, the Pertussis Therapeutics Market presents significant growth potential in the coming years.

Understanding Pertussis and Its Diagnosis

Pertussis, commonly known as whooping cough, is a severe respiratory infection caused by Bordetella pertussis. The illness progresses through three stages: catarrhal, paroxysmal, and convalescent. Accurate diagnosis is critical but challenging, involving tests like culture, PCR, single sera, and paired sera—the latter being the most reliable for confirming infection.

Prevention and Treatment

Vaccination remains the cornerstone of pertussis prevention. In the U.S., DTaP and Tdap vaccines are widely administered, with all adolescents and adults recommended to receive at least three doses. The Pertussis Drugs Market primarily includes macrolide antibiotics such as erythromycin, clarithromycin, and azithromycin. While effective, side effects can affect adherence, making supportive care—like oxygen therapy, hydration, and avoiding respiratory irritants—an essential part of treatment.

Epidemiology and Market Size

According to DelveInsight, approximately 19 million individuals in the U.S. were vaccinated in 2022, including 5 million adults who received booster doses. Across the seven major markets (7MM), around 34 million people received vaccinations in the same year. These numbers are expected to rise, driven by increasing awareness, updated immunization guidelines, and innovative vaccines. The total Pertussis Treatment Market Size in the 7MM was estimated at $3.5 billion in 2022, with the U.S. as the leading contributor.

Vaccine Landscape

Key vaccines driving the Pertussis Therapeutics Market include:

ADACEL (Sanofi Pasteur): A trivalent booster for pertussis, tetanus, and diphtheria, available in 55 countries.
BOOSTRIX (GSK): Recommended for individuals aged 10 and above, including maternal immunization programs.

Emerging candidates include:

BPZE1 (ILiAD Biotechnologies): An intranasal booster in Phase IIb with FDA Fast Track designation.
BK1310/MT-2355 (Mitsubishi Tanabe Pharma): A 5-in-1 combination vaccine planned for launch in Japan in FY2023.

Market Outlook and Competitive Dynamics

Complete immunization is vital to controlling pertussis. While childhood vaccination rates are high in the 7MM, adult booster compliance remains relatively low. The market is highly competitive in the U.S. and Europe, with vaccines like PEDIARIX, PENTACEL, and Vaxelis shaping dynamics. In Japan, Mitsubishi leads the market with TETRABIK.

The report also evaluates adoption rates for recently launched and pipeline vaccines, patient uptake trends, sales performance, and market share. Insights into regulatory progress, collaborations, patent filings, and reimbursement scenarios help identify economically attractive markets and potential challenges.